NEW YORK, January 27, 2015 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including D.R. Horton (NYSE: DHI), MeadWestvaco (NYSE: MWV), Ocwen (NYSE: OCN), Microsoft (NASDAQ: MSFT), and Array (NASDAQ: ARRY). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
DHI Research Report: ( http://get.analystsreview.com/pdf/?c=D.R.%20Horton&d=27-Jan-2015&s=DHI ),
MWV Research Report: ( http://get.analystsreview.com/pdf/?c=MeadWestvaco&d=27-Jan-2015&s=MWV ),
OCN Research Report: ( http://get.analystsreview.com/pdf/?c=Ocwen&d=27-Jan-2015&s=OCN ),
MSFT Research Report: ( http://get.analystsreview.com/pdf/?c=Microsoft&d=27-Jan-2015&s=MSFT ),
ARRY Research Report: ( http://get.analystsreview.com/pdf/?c=Array&d=27-Jan-2015&s=ARRY ).
Analyst Update: Quarterly Earnings, Agreement, and Corporate Updates
Reviewed by: Rohit Tuli, CFA®
The U.S. stocks edged higher on Monday, helped by rise in energy shares which also overshadowed the concerns that victory of anti-bailout party Syriza in Greece could bring a fresh crisis to the Euro zone. Syriza's 40-year old leader Alexis Tsipras has vowed to renegotiate Greece's €240 million bailout deal and bring about an end to the austerity measures. The Dow Jones Industrial Average added 0.03% to close at 17,678.70, the S&P 500 gained 0.26% to close at 2,057.09, and the Nasdaq Composite rose 0.29% to end at 4,771.76. European stocks also ended higher on Monday after an initial slide following the outcome of Greece elections. Riding high on the European Central Bank's recently announced bond-buying program, the Stoxx Europe 600 index rose for the eighth straight session on Monday, hitting a fresh seven-year high. In Asia, most of the equity markets managed to end the session higher despite renewed concerns over Greece's future in Euro zone.
D.R. Horton, Inc. (D.R. Horton), the largest homebuilder by volume in the U.S., has reported better-than-expected results for first quarter fiscal 2015, helped by strong growth in the new home sales. Shares of D.R. Horton rose 5.54% on Monday to close at $24.38. Read more about D.R. Horton's performance in the first quarter in our exclusive research report.
Shares of the Richmond-Virginia based MeadWestvaco Corp. (MeadWestvaco) climbed to a new 52-week high on Monday after the Company announced agreement to merge with Rock-Tenn Company ("RockTenn") to create a $16 billion packaging giant. The companies expect to achieve total annual synergies of $300 million over three years. Continue reading about MeadWestvaco's merger agreement with all the details in our exclusive research report.
Shares of the Ocwen Financial Corp. (Ocwen) jumped nearly 9% on Monday after the Company said that it has avoided California license suspension following a settlement agreement with the California Department of Business Oversight (CA DBO). Ocwen's wholly-owned subsidiary Ocwen Loan Servicing, LLC (OLS) has agreed to pay $2.5 million to the CA DBO for the settlement. Read more about the Ocwen's agreement with California and its response to the allegations made by certain investor groups in our detailed research report.
Microsoft Corporation (Microsoft) has reported second quarter fiscal 2015 sales and net income that beat the market expectations as the U.S.-based software maker benefited from continued growth in commercial cloud services. Microsoft's profit excluding special items was $0.77 per share in the quarter, beating the average analyst estimates of $0.75 per share in a Bloomberg's poll. Continue reading about Microsoft's financial performance in the second quarter in our comprehensive research report.
Array BioPharma Inc. (Array) has entered into an agreement with Novartis Pharma AG (Novartis) to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development. The deal is conditional on Novartis closing its previously announced transactions with GlaxoSmithKline. Know more about Array's agreement with Novartis in our exclusive research report.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review